The Anti-α4β7 Integrin Therapeutic Antibody for Inflammatory Bowel Disease, Vedolizumab, Ameliorates Eosinophilic Esophagitis: a Novel Clinical Observation.
The Anti-α4β7 Integrin Therapeutic Antibody for Inflammatory Bowel Disease, Vedolizumab, Ameliorates Eosinophilic Esophagitis: a Novel Clinical Observation.
复制标题
用于炎症性肠病的抗α4β7 整合素治疗抗体，Vedolizumab，改善嗜酸粒细胞性食管炎：一项新的临床观察。
DOI：
10.1038/s41395-018-0145-1
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Konijeti,GaureeG
中科院分区：
文献类型：
--
作者：
Nhu,QuanM;Chiao,Hellen;Moawad,FouadJ;Bao,Fei;Konijeti,GaureeG
3.Devarbhavi H.阿育吠陀和草药引起的肝损伤：是时候醒醒和注意了。印度J胃肠激素。2018年；37：5-7。https://doi.Org/10.1007/s12664-0180820-6.4.Al-Eryani L，Wahlang B，Falkner KC，Guardiola JJ，Clair HB，ProughRA等人。与啮齿动物毒物相关性脂肪性肝病发展相关的环境化学物质的鉴定。毒素帕索尔。2015年；43：482-97。
3. Devarbhavi H. Ayurvedic and herbal medicineinduced liver injury: it is time to wake up and take notice. Indian J Gastroenterol. 2018; 37: 5–7. https://doi. org/10.1007/s12664-018-0820-6. 4. Al-Eryani L, Wahlang B, Falkner KC, Guardiola JJ, Clair HB, Prough RA, et al. Identification of environmental chemicals associated with the development of toxicant-associated fatty liver disease in rodents. Toxicol Pathol. 2015; 43: 482–97.